Antibodies capable of neutralizing the heterologous MuV genotypes in the absence of antigenic boosting demonstrated a decrease to the critical levels ( 1:8) in a part of vaccinees after the third year post vaccination, while the specific IgG neutralizing activity against the vaccine strain still demonstrated a titer previously associated with protection against MuV infection ( 1:8).